Drug intelligence / Profile preview

Rabies Vaccine (Serum-free Vero Cell)

Development stage: Phase 3
Lead developer: Sinovac Biotech
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

This is an inactivated rabies vaccine produced in Vero cells using a serum-free medium. It is designed to induce immunity against the rabies virus by stimulating the production of neutralizing antibodies. The vaccine is used for both pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) to prevent rabies. Sinovac Biotech Co., Ltd. is developing and manufacturing this specific vaccine.

Brand names: Inlive
Other names: rabies vaccine (serum-free vero cell)Rabies Vaccine (Serum-free Vero Cell), Freeze-driedHuman Rabies Vaccine (Vero Cell Serum-free)

Targets

RABV-G (Rabies virus glycoprotein)

Beyond the preview

Go deeper on Rabies Vaccine (Serum-free Vero Cell).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rabies Vaccine (Serum-free Vero Cell).

Explore the full profile